Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News IDEAYA Biosciences Inc IDYA

Healthcare Biotechnology
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a... see more

Current News (NDAQ:IDYA)

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

PR Newswire December 11, 2025

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers

PR Newswire December 10, 2025

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types

PR Newswire December 1, 2025

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire November 28, 2025

IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events

PR Newswire November 24, 2025

IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

PR Newswire November 4, 2025

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PR Newswire October 31, 2025

IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events

PR Newswire October 27, 2025

IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025

PR Newswire October 20, 2025
View More News ››

Opinion & Analysis (NDAQ:IDYA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IDYA)

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$IDYA $NKTR $MGNX $CTMX $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7...
AviseAnalytics - January 26, 2022
View more Bullboard ››

Sranan Gold Corp.

Sranan Gold Corp.

Sranan Gold Corp. develops, acquires, and explores mineral properties in Canada. The company primarily explores gold deposits ...
View More »

Podcasts